Debora Fumagalli
Overview
Explore the profile of Debora Fumagalli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi M, et al.
J Natl Cancer Inst
. 2022 May;
114(8):1117-1126.
PMID: 35512402
Background: Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in...
2.
Gelber R, Wang X, Cole B, Cameron D, Cardoso F, Tjan-Heijnen V, et al.
Eur J Cancer
. 2022 Mar;
166:219-228.
PMID: 35313167
Aim: The APHINITY trial showed that adding adjuvant pertuzumab (P) to trastuzumab and chemotherapy, compared with adding placebo (Pla), significantly improved invasive disease-free survival (IDFS) for patients with HER2+ early...
3.
Malorni L, Tyekucheva S, Hilbers F, Ignatiadis M, Neven P, Colleoni M, et al.
Eur J Cancer
. 2022 Feb;
164:39-51.
PMID: 35172272
Background: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent...
4.
Pizzamiglio S, Ciniselli C, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6307-6313.
PMID: 34548320
Purpose: Little is known about the efficacy of HER2-targeted therapy in patients with breast cancer showing different HER2-pathway dependence and immune phenotypes. Herein, we report a NeoALTTO exploratory analysis evaluating...
5.
Venet D, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, et al.
Clin Cancer Res
. 2021 Jul;
27(20):5607-5618.
PMID: 34321278
Purpose: The heterogeneity of response to anti-HER2 agents represents a major challenge in patients with HER2-positive breast cancer. To better understand the sensitivity and resistance to trastuzumab and lapatinib, we...
6.
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, et al.
Cancer Discov
. 2021 Jun;
11(11):2796-2811.
PMID: 34183353
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and...
7.
Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al.
N Engl J Med
. 2021 Jun;
384(25):2394-2405.
PMID: 34081848
Background: Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with or germline mutation-associated early...
8.
Solinas C, Fumagalli D, Dieci M
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33916115
The present commentary synthesizes the current evidence on the role of the immune response in HER2-positive breast cancer. It points out the strengths and weaknesses of the findings observed so...
9.
Bines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A, et al.
Br J Cancer
. 2021 Apr;
125(1):38-47.
PMID: 33828257
Background: We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Methods: Patients received 1...
10.
Chic N, Luen S, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, et al.
J Natl Cancer Inst
. 2021 Mar;
114(3):467-470.
PMID: 33787900
In early-stage HER2-positive breast cancer, biomarkers that guide deescalation and/or escalation of systemic therapy are needed. CelTIL score is a novel, combined biomarker based on stromal tumor-infiltrating lymphocytes and tumor...